Secretory phospholipase A2-IIA and cardiovascular disease: A mendelian randomization study

Journal of the American College of Cardiology

Volumn 62, Issue 21, 2013, Pages 1966-1976

  Holmes, Michael V ^a   Simon, Tabassome ^b,c   Exeter, Holly J ^a   Folkersen, Lasse ^d,e   Asselbergs, Folkert W ^f,g   Guardiola, Montse ^h   Cooper, Jackie A ^a   Palmen, Jutta ^a   Hubacek, Jaroslav A ⁱ   Carruthers, Kathryn F ^j   Horne, Benjamin D ^k,l   Brunisholz, Kimberly D ^k   Mega, Jessica L ^m   Van Iperen, Erik P A ^o   Li, Mingyao ^p   Leusink, Maarten ^q   Trompet, Stella ^r   Verschuren, Jeffrey J W ^r   Hovingh, G Kees ^o   Dehghan, Abbas ^s,t   Nelson, Christopher P ^u,v   Kotti, Salma ^b   Danchin, Nicolas ^w,x   Scholz, Markus ^y   Haase, Christiane L ^z   Rothenbacher, Dietrich ^aa,ab   Swerdlow, Daniel I ^a   Kuchenbaecker, Karoline B ⁿ   Staines Urias, Eleonora ^ac   Goel, Anuj ^ad,ae   Van 'T Hooft, Ferdinand ^d,e   Gertow, Karl ^d,e   De Faire, Ulf ^d   Panayiotou, Andrie G ^af   Tremoli, Elena ^ag,ah   Baldassarre, Damiano ^ag,ah   Veglia, Fabrizio ^ah   Holdt, Lesca M ^y,ai,as   Beutner, Frank ^y   Gansevoort, Ron T ^aj   Navis, Gerjan J ^aj   Mateo Leach, Irene ^aj   Breitling, Lutz P ^ab   Brenner, Hermann ^ab   Thiery, Joachim ^y,ai   Dallmeier, Dhayana ^ak   Franco Cereceda, Anders ^d   Boer, Jolanda M A ^al   Stephens, Jeffrey W ^am   Hofker, Marten H ^aj   Tedgui, Alain ^an   Hofman, Albert ^s,t   Uitterlinden, André G ^s,t   Adamkova, Vera ⁱ   Pitha, Jan ⁱ   Onland Moret, N Charlotte ^f   Cramer, Maarten J ^f   Nathoe, Hendrik M ^f   Spiering, Wilko ^f   Klungel, Olaf H ^q   Kumari, Meena ^a   Whincup, Peter H ^ao   Morrow, David A ^m   Braund, Peter S ^u   Hall, Alistair S ^ap   Olsson, Anders G ^aq   Doevendans, Pieter A ^f   Trip, Mieke D ^o   Tobin, Martin D ^u   Hamsten, Anders ^d,e   Watkins, Hugh ^ad,ae   Koenig, Wolfgang ^ak   Nicolaides, Andrew N ^ar   Teupser, Daniel ^y,ai,as   Day, Ian N M ^b   Carlquist, John F ^k,l   Gaunt, Tom R ^at   Ford, Ian ^au   Sattar, Naveed ^av   Tsimikas, Sotirios ^aw   Schwartz, Gregory G ^ax   Lawlor, Debbie A ^at   Morris, Richard W ^a   Sandhu, Manjinder S ^ax   Poledne, Rudolf ⁱ   Maitland Van Der Zee, Anke H ^q   Khaw, Kay Tee ⁿ   Keating, Brendan J ^ay   Van Der Harst, Pim ^aj   Price, Jackie F ^az   Mehta, Shamir R ^ba,bb   Yusuf, Salim ^bb   Witteman, Jaqueline C M ^s,t   Franco, Oscar H ^s,t   Jukema, J Wouter ^r,bc   De Knijff, Peter ^r   Tybjaerg Hansen, Anne ^z   Rader, Daniel J ^bd   Farrall, Martin ^ad,ae   Samani, Nilesh J ^u,v   Kivimaki, Mika ^a   Fox, Keith A A ^j   Humphries, Steve E ^a   Anderson, Jeffrey L ^k,l   Boekholdt, S Matthijs ^o   Palmer, Tom M ^be   Eriksson, Per ^d,e   Paré, Guillaume ^ba,bb   Hingorani, Aroon D ^a   Sabatine, Marc S ^m   Mallat, Ziad ^n,an   Casas, Juan P ^a,ac   Talmud, Philippa J ^a   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HÔPITAL SAINT ANTOINE   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d KAROLINSKA INSTITUTE   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g Durrer Center for Cardiogenetic Research   (Netherlands)

^h INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

ⁱ INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^j UNIVERSITY OF EDINBURGH   (United Kingdom)

^k INTERMOUNTAIN MEDICAL CENTER   (United States)

^l UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁿ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^o UNIVERSITY OF AMSTERDAM   (Netherlands)

^p UNIVERSITY OF PENNSYLVANIA   (United States)

^q UTRECHT UNIVERSITY   (Netherlands)

^r LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^s ERASMUS MEDICAL CENTER   (Netherlands)

^t Netherlands Consortium on Healthy Aging (NCHA)   (Netherlands)

^u UNIVERSITY OF LEICESTER   (United Kingdom)

^v GLENFIELD HOSPITAL   (United Kingdom)

^w HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^x UNIVERSITÉ PARIS DESCARTES   (France)

^y UNIVERSITY OF LEIPZIG   (Germany)

^z Rigshospitalet   (Denmark)

^aa UNIVERSITY OF ULM   (Germany)

^ab GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^ac LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^ad UNIVERSITY OF OXFORD   (United Kingdom)

^ae UNIVERSITY OF OXFORD   (United Kingdom)

^af Cyprus Cardiovascular Disease Educational and Research Trust   (Cyprus)

^ag UNIVERSITY OF MILAN   (Italy)

^ah CENTRO CARDIOLOGICO MONZINO   (Italy)

^ai UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^aj UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^ak UNIVERSITY HOSPITAL ULM   (Germany)

^al NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^am SWANSEA UNIVERSITY   (United Kingdom)

^an PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^ao ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^ap UNIVERSITY OF LEEDS   (United Kingdom)

^aq LINKÖPING UNIVERSITY   (Sweden)

^ar IMPERIAL COLLEGE LONDON   (United Kingdom)

^as LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^at UNIVERSITY OF BRISTOL   (United Kingdom)

^au UNIVERSITY OF GLASGOW   (United Kingdom)

^av UNIVERSITY OF GLASGOW   (United Kingdom)

^aw UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^ax VETERANS AFFAIRS MEDICAL CENTER   (United States)

^ay CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^az UNIVERSITY OF EDINBURGH   (United Kingdom)

^ba MCMASTER UNIVERSITY   (Canada)

^bb HAMILTON HEALTH SCIENCES   (Canada)

^bc ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^bd Preventive Cardiovascular Medicine   (United States)

^be UNIVERSITY OF WARWICK   (United Kingdom)

more..

Author keywords

cardiovascular diseases; drug development; epidemiology; genetics; Mendelian randomization

Indexed keywords

ISOENZYME; SECRETORY PHOSPHOLIPASE A2; SECRETORY PHOSPHOLIPASE A2 IIA; UNCLASSIFIED DRUG; VARESPLADIB;

ACUTE CORONARY SYNDROME; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; INSTRUMENTAL VARIABLE ANALYSIS; MENDELIAN RANDOMIZATION ANALYSIS; META ANALYSIS (TOPIC); OBSERVATIONAL METHOD; PRIORITY JOURNAL;

ACS; ACUTE CORONARY SYNDROME(S); CARDIOVASCULAR DISEASES; CI; CONFIDENCE INTERVAL; DRUG DEVELOPMENT; EPIDEMIOLOGY; GENETICS; LDL-C; LOW-DENSITY LIPOPROTEIN CHOLESTEROL; MAJOR VASCULAR EVENTS; MENDELIAN RANDOMIZATION; MI; MVE; MYOCARDIAL INFARCTION; ODDS RATIO; OR; RANDOMIZED CLINICAL TRIAL; RCT; SECRETORY PHOSPHOLIPASE A(2); SINGLE-NUCLEOTIDE POLYMORPHISM; SNP; SPLA(2);

ALLELES; CARDIOVASCULAR DISEASES; DNA; GENE EXPRESSION REGULATION; HUMANS; INCIDENCE; MENDELIAN RANDOMIZATION ANALYSIS; PHOSPHOLIPASES A2, SECRETORY; WORLD HEALTH;

EID: 84888256840     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.06.044     Document Type: Article

References (25)

1. R.S. Rosenson, and E. Hurt-Camejo Phospholipase A2 enzymes and the risk of atherosclerosis Eur Heart J 33 2012 2899 2909
2. Z. Mallat, G. Lambeau, and A. Tedgui Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers Circulation 122 2010 2183 2200
3. Z. Mallat, P.G. Steg, and J. Benessiano Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes J Am Coll Cardiol 46 2005 1249 1257
4. S.M. Boekholdt, T.T. Keller, and N.J. Wareham Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study Arterioscler Thromb Vasc Biol 25 2005 839 846
5. Z. Mallat, J. Benessiano, and T. Simon Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study Arterioscler Thromb Vasc Biol 27 2007 1177 1183
6. M.L. O'Donoghue, Z. Mallat, and D.A. Morrow Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease Clin Chem 57 2011 1311 1317
7. S.K. Ryu, Z. Mallat, and J. Benessiano Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes Circulation 125 2012 757 766
8. U.J. Tietge, D. Pratico, and T. Ding Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress J Lipid Res 46 2005 1604 1614
9. V. Dzavik, S. Lavi, and K. Thorpe The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial Circulation 122 2010 2411 2418
10. S.J. Nicholls, M.A. Cavender, and J.J. Kastelein Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial Cardiovasc Drugs Ther 26 2012 71 75
11. Clinical Study Report for Study AN-CVD2233. Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects with Acute Coronary Syndromes. 2012. Available at: http://www.anthera.com/VISTA-16.pdf. Accessed September 2013.
12. D.W. Snyder, N.J. Bach, and R.D. Dillard Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: a new class of anti-inflammatory drugs, SPI J Pharmacol Exp Ther 288 1999 1117 1124
13. H. Fraser, C. Hislop, and R.M. Christie Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice J Cardiovasc Pharmacol 53 2009 60 65
14. F. Innocenti, G.M. Cooper, and I.B. Stanaway Identification, replication, and functional fine-mapping of expression quantitative trait loci in primary human liver tissue PLoS Genet 7 2011 e1002078
15. P.T. Wootton, F. Drenos, and J.A. Cooper Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study Hum Mol Genet 15 2006 355 361
16. D.A. Lawlor, R.M. Harbord, J.A. Sterne, and N. Timpson Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology Stat Med 27 2008 1133 1163
17. J.R. Thompson, C. Minelli, K.R. Abrams, M.D. Tobin, and R.D. Riley Meta-analysis of genetic studies using Mendelian randomization - a multivariate approach Stat Med 24 2005 2241 2254
18. D.C. Thomas, D.A. Lawlor, and J.R. Thompson Re: estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al Ann Epidemiol 17 2007 511 513
19. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 6 2009 e1000097
20. R.S. Rosenson, C. Hislop, M. Elliott, Y. Stasiv, M. Goulder, and D. Waters Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients J Am Coll Cardiol 56 2010 1079 1088
21. R.S. Rosenson, C. Hislop, and D. McConnell Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial Lancet 373 2009 649 658
22. R.S. Rosenson, M. Elliott, Y. Stasiv, and C. Hislop Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease Eur Heart J 32 2011 999 1005
23. S. Padmanabhan, C. Newton-Cheh, and A.F. Dominiczak Genetic basis of blood pressure and hypertension Trends Genet 28 2012 397 408
24. T.M. Teslovich, K. Musunuru, and A.V. Smith Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
25. C. Minelli, J.R. Thompson, M.D. Tobin, and K.R. Abrams An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization Am J Epidemiol 160 2004 445 452